Regeneron Pharmaceuticals, Inc. (REGN)
-NasdaqGS 250.31 
4.56(1.79%) May 24, 4:00PM EDT|After Hours
:
251.24 0.93 (0.37%) May 24, 5:00PM EDT
| Prev Close: | 254.87 |
|---|
| Open: | 253.60 |
|---|
| Bid: | N/A |
|---|
| Ask: | 252.40 x 1200 |
|---|
| 1y Target Est: | 287.94 |
|---|
| Beta: | 0.84 |
|---|
| Next Earnings Date: | 22-Jul-13 |
|---|
| Day's Range: | 246.22 - 254.69 |
|---|
| 52wk Range: | 107.31 - 283.99 |
|---|
| Volume: | 676,528 |
|---|
| Avg Vol (3m): | 1,100,940 |
|---|
| Market Cap: | 24.25B |
|---|
| P/E (ttm): | 33.47 |
|---|
| EPS (ttm): | 7.48 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Meet the 4 Newest Members of the S&P 500at Motley Fool(Sat 11:31AM EDT)
- Today’s 3 Worst Stocksat Motley Fool(Thu, May 23)
- Regeneron Pharmaceuticals Inc. (REGN): Today's Featured Drugs Laggardat TheStreet(Thu, May 23)
- Agree To Buy Regeneron Pharmaceuticals At $165, Earn 9.8%at Forbes(Thu, May 23)
- Amgen Stock Checkup for Mayat Motley Fool(Thu, May 23)
- Applied Materials CEO Sells 300K Shares and 4 Insider Sales to Noteat Wall St. Cheat Sheet(Thu, May 23)
- Is This Momentum Stock’s Rally Over?at Motley Fool(Wed, May 22)
- Sanofi/REGN's Dupilumab Data PublishedZacks(Wed, May 22)
- Regeneron Shareholders Watching Optina Trial Closelyat Seeking Alpha(Wed, May 22)
- Regeneron moves higher on asthma drug study dataAP(Wed, May 22)
- Stocks Stage Broad Advance; Bristol-Myers Leads Medicalsat Investor's Business Daily(Wed, May 22)
- Regeneron and Sanofi: An Unstoppable Biotech Duo?at Motley Fool(Tue, May 21)
- Regeneron, Sanofi asthma drug seen as potential game changerat Reuters(Tue, May 21)
- New Drug May Help Some Asthmatics, Study Findsat New York Times(Tue, May 21)
- New Asthma Drug Generates Excitement For Patients -- And Its Makerat Forbes(Tue, May 21)
Key Statistics
| Forward P/E (1 yr): | 41.24 |
|---|
| P/S (ttm): | 15.56 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 3.87 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 0.92 |
|---|
| Mean Recommendation*: | 2.2 |
|---|
| PEG Ratio (5 yr expected): | 2.63 |
|---|
Business Summary
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally.
View More